# Efficacy and Safety of Wei Li Bai Capsules in the Treatment of Alzheimer's Disease

> **NCT05670912** · PHASE2 · TERMINATED · sponsor: **Capital Medical University** · enrollment: 105 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Wei Li Bai capsules
- **DRUG:** Placebo Comparator of Wei Li Bai capsules

## Key facts

- **NCT ID:** NCT05670912
- **Lead sponsor:** Capital Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-10-01
- **Primary completion:** 2024-11-12
- **Final completion:** 2024-11-12
- **Target enrollment:** 105 (ACTUAL)
- **Why stopped:** Due to the inability to complete subject enrollment and follow-up as originally scheduled, coupled with funding shortages and overall strategic adjustments from the sponsor, the study was terminated on November 12, 2024.
- **Last updated:** 2024-12-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05670912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05670912, "Efficacy and Safety of Wei Li Bai Capsules in the Treatment of Alzheimer's Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05670912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*